Valuation: CASI Pharmaceuticals, Inc.

Market Cap 2.26M 2.06M 1.9M 1.73M 3.24M 209M 3.4M 23.08M 9.17M 114M 8.48M 8.3M 359M P/E 2024
-1.11x
P/E 2025 -0.33x
Enterprise Value 24.11M 21.96M 20.24M 18.41M 34.54M 2.23B 36.3M 246M 97.9M 1.22B 90.48M 88.57M 3.83B EV / Sales 2024
1.75x
EV / Sales 2025 1.9x
Free-Float
53.46%
Yield 2024 *
-
Yield 2025 -
1 day+9.94%
1 week+7.78%
Current month-15.51%
1 month+9.83%
3 months-14.64%
6 months-8.38%
Current year-87.07%
1 week 0.1
Extreme 0.1
0.11
1 month 0.1
Extreme 0.1
0.13
Current year 0.05
Extreme 0.05
1.2
1 year 0.05
Extreme 0.05
1.24
3 years 0.05
Extreme 0.05
8.48
5 years 0.05
Extreme 0.05
10.3
10 years 0.05
Extreme 0.05
88.92
Manager TitleAgeSince
Chief Executive Officer 62 2025-07-20
Director of Finance/CFO 44 2025-05-15
Chief Operating Officer 54 2016-12-31
Director TitleAgeSince
Director/Board Member 62 2013-03-31
Director/Board Member 50 2023-03-20
Director/Board Member 59 2023-03-20
Date Insider Type Main position Quantity % Market Cap. Importance
3/18/26
Emerging Technology Partners LLC
OtherCompany 1,097,341 7.0830%
3/18/26
Panacea Venture
OtherCompany 4,529,956 29.2393%
3/18/26 Other

Chief Financial Officer

75,000 0.4841%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%+7.78%-91.06%-98.07% 2.26M
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +1.29%-3.29%+13.41%+58.27% 407B
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2024 2025
Net sales 28.54M 25.99M 23.95M 21.79M 40.87M 2.64B 42.95M 291M 116M 1.44B 107M 105M 4.53B 20.71M 18.86M 17.38M 15.81M 29.66M 1.92B 31.18M 212M 84.08M 1.05B 77.71M 76.07M 3.29B
Net income -39.26M -35.76M -32.95M -29.97M -56.22M -3.64B -59.09M -401M -159M -1.99B -147M -144M -6.23B -48.06M -43.77M -40.33M -36.69M -68.83M -4.45B -72.34M -491M -195M -2.43B -180M -177M -7.63B
Net Debt 6.05M 5.51M 5.08M 4.62M 8.66M 560M 9.11M 61.8M 24.56M 306M 22.7M 22.22M 960M 21.85M 19.9M 18.34M 16.68M 31.3M 2.02B 32.89M 223M 88.72M 1.11B 82M 80.27M 3.47B
Projected Income Statement - Annual - CASI Pharmaceuticals, Inc.
Logo CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
Employees
214
Date Price Change Volume
26-11-20 US$0.1099 +9.94% 22,174
26-11-19 US$0.1000 -.--% 235
26-11-16 US$0.1000 -1.96% 10,115
26-11-13 US$0.1020 +2.00% 260
  1. Stock Market
  2. Stocks
  3. CASIF Stock